ACT Brief: RBQM Financial Value Quantified, Sponsor-Configurable AI Systems, and Basket Trials for Rare Pediatrics

This is the Applied Clinical Trials Brief—your fast track to the latest insights shaping clinical operations and drug development.

• In new research, the Tufts Center for the Study of Drug Development quantified RBQM's financial impact on a Phase III oncology trial at $13.8 million net value, with 84% from time savings through early risk identification and 16% from monitoring cost reductions. Clinical trial-level ROI multiples ranged from 6.1× to 22.7× across phases, with program-level eNPV deltas strongest in Phase III reflecting late-stage cost and scheduling consequences.
• In part four of his interview, Raj Indupuri of eClinical Solutions described how allowing sponsors to inject their own SOPs, protocols, and governance frameworks into AI systems is key to building the trust needed for real-world adoption. When organizations maintain control over decision rules and compliance frameworks, AI becomes a tool aligned with their risk tolerance rather than an external mandate.
• In another segment of a Pharmaceutical Executive interview, Lisa Bollinger of Polaryx discussed how basket trials are reshaping rare pediatric oncology development by enabling recruitment at specialized treatment centers and leveraging Bayesian approaches to borrow data across related indications. A single basket trial at multiple sites is operationally more efficient than standing up individual trials for each rare disease, improving both feasibility and evidence generation.

That's all for today's ACT Brief. Join us next week for more updates shaping clinical operations and drug development. Thanks for listening.